Drug intelligence / Profile preview

phoxilium

Development stage: Unknown
Lead developer: Takeda
Modality: Small Molecules
Administration: Intravenous

Overview

Phoxilium is a renal replacement solution used in Continuous Renal Replacement Therapy (CRRT) for critically ill patients with acute renal failure. It contains a balanced combination of electrolytes including sodium, calcium, magnesium, potassium, phosphate, and chloride ions at concentrations similar to physiological levels in normal plasma. It's specifically designed to replace plasma volume removed by ultrafiltration, correct electrolyte and acid-base imbalances, and prevent hypophosphatemia during CRRT.

Brand names: PhoxiliumPhoxillum

Beyond the preview

Go deeper on phoxilium.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on phoxilium.

Explore the full profile